Literature DB >> 11581532

Rasmussen's Encephalitis.

Dianne Counce1, Nita Limdi, Ruben Kuzniecky.   

Abstract

When the diagnosis of Rasmussen's encephalitis is being considered, it is important to rapidly exclude other causes of epilepsia partialis continua and hemiparesis. Although there is no good data from randomized trials of different immune-related therapies, treatment with immunoglobulin G (IgG), steroids, or plasmapheresis is advocated as first-line therapy. It is not unreasonable to institute at least two treatment options (eg, IgG followed by plasmapheresis) if response to the first treatment is poor. Functional hemispherectomy and its variants are associated with a lower long-term complication rate.

Entities:  

Year:  2001        PMID: 11581532     DOI: 10.1007/s11940-001-0018-5

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  35 in total

1.  Early detection of Rasmussen's syndrome by brain SPECT imaging.

Authors:  G J Burke; S A Fifer; J Yoder
Journal:  Clin Nucl Med       Date:  1992-09       Impact factor: 7.794

2.  Hemispherectomy for seizures.

Authors:  M A Bare
Journal:  J Neurosci Nurs       Date:  1989-02       Impact factor: 1.230

3.  MRI and proton spectroscopy in a child with Rasmussen's encephalitis. Case report.

Authors:  P C Sundgren; I M Burtscher; J Lundgren; B Geijer; S Holtås
Journal:  Neuroradiology       Date:  1999-12       Impact factor: 2.804

4.  Rasmussen's encephalitis with concomitant cortical dysplasia: the role of GluR3.

Authors:  C A Palmer; J D Geyer; J M Keating; F Gilliam; R I Kuzniecky; R B Morawetz; E M Bebin
Journal:  Epilepsia       Date:  1999-02       Impact factor: 5.864

5.  Treatment of Rasmussen's syndrome with ganciclovir.

Authors:  R S McLachlan; S Levin; W T Blume
Journal:  Neurology       Date:  1996-10       Impact factor: 9.910

6.  Complications of intravenous gammaglobulin in neuromuscular and other diseases.

Authors:  T E Bertorini; A M Nance; L H Horner; W Greene; M S Gelfand; J H Jaster
Journal:  Muscle Nerve       Date:  1996-03       Impact factor: 3.217

7.  Improvement in adult-onset Rasmussen's encephalitis with long-term immunomodulatory therapy.

Authors:  J P Leach; D W Chadwick; J B Miles; I K Hart
Journal:  Neurology       Date:  1999-03-10       Impact factor: 9.910

8.  Glutamate receptor antibodies activate a subset of receptors and reveal an agonist binding site.

Authors:  R E Twyman; L C Gahring; J Spiess; S W Rogers
Journal:  Neuron       Date:  1995-04       Impact factor: 17.173

9.  Rasmussen's syndrome: a study of potential viral etiology.

Authors:  M R Atkins; W Terrell; C M Hulette
Journal:  Clin Neuropathol       Date:  1995 Jan-Feb       Impact factor: 1.368

10.  Plasmapheresis in Rasmussen's encephalitis.

Authors:  P I Andrews; M A Dichter; S F Berkovic; M R Newton; J O McNamara
Journal:  Neurology       Date:  1996-01       Impact factor: 9.910

View more
  1 in total

1.  Inflammasome induction in Rasmussen's encephalitis: cortical and associated white matter pathogenesis.

Authors:  Vijay Ramaswamy; John G Walsh; D Barry Sinclair; Edward Johnson; Richard Tang-Wai; B Matt Wheatley; William Branton; Ferdinand Maingat; Thomas Snyder; Donald W Gross; Christopher Power
Journal:  J Neuroinflammation       Date:  2013-12-13       Impact factor: 8.322

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.